The Efficacy Evaluation Of Extensive TURBT With Repeatand Transurethral Resection In The Treatment Of NMIBC

OBJECTIVE: Through the comparison of the clinical curative effect of repeat transurethral resection after extensive TURBT and only extensive TURBT in the treatment of non-muscle-invasive bladder cancer,to explore the effect of repeat transurethral resection after extensive TURBT on the prognosis of non-muscle invasive bladder cancer.METHODS: We retrospectively analyzed 105 cases of patients with non-muscle-invasive bladder cancer who underwent transurethral resection from January 2015 to December 2016 in the Second Hospital of Tianjin Medical University hospital.The patients were divided into a study group and a control group according to whether or not the reTURBT was performed 2-6 weeks after the first extensive TURBT,of which 28 were in the reTURBT group and 77 were in the exTURBT group.All patients received early and subsequent postoperative bladder instillation(hydroxycamptothecin,epirubicin,or gemcitabine)and were routinely reviewed for cystoscopy.The two groups of patients were followed up for more than 1 year.Observe the difference of the two pathological results a before and after the retur and the residual rate of the tumor after the initial resection,and compare the tumor recurrence between the two groups.RESULTS: There was no statistical difference between the two groups in age,gender,tumor size and number,and tumor pathological status(stage and grade)(p>0.05).The postoperative pathological findings of the study group showed that there was 1 case of tumor residue(the positive rate was 3.57%),reTURBT group recurred within 3 cases(10.71%),and the control group recurred in 8 cases(10.39%).By comparison,it was found that there was a statistically significant between the two groups in the diffence of the recurrence rate within one year(p<0.05).CONCLUSION: Repeat transurethral resection after extensive TURBT versus only enlarged TURBT were not significantly different in the recurrence rate of non-muscle-invasive bladder cancer.The clinical efficacy of reTURBT after ex TURBT in patients is not significant,and patients who have already had exTURBT should choose reTURBT carefully.